Addex Therapeutics (APE1) Stock Price & Analysis
APE1 Stock Chart & Stats
- Day’s Range
- EUR 2.60 - EUR 2.66
- 52-Week Range
- EUR 2.28 - EUR 7.80
- Previous Close
- EUR 2.54
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 3.14M
- Enterprise Value
- EUR 4.97M
- Total Cash (Recent Filing)
- EUR 767.33K
- Total Debt (Recent Filing)
- EUR 77.50K
- Price to Earnings (P/E)
- ―
- Beta
- 1.02
- Next Earnings
- Nov 09, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Advancing CNS Pipeline
The lead GABAB PAM candidate has cleared IND-enabling work and is ready to enter clinical development, while several other CNS programs are advancing. This breadth creates multiple opportunities for clinical validation, partnering, and future milestone value rather than relying on one asset.
Broad Platform And Intellectual Property
Regaining full rights expands Addex’s ability to develop GABAB PAM candidates across indications and negotiate partnerships without the prior license constraint. A young patent portfolio with potential protection through 2044 could support durable exclusivity if the applications are granted.
Extended Cash Runway
The financing extends the stated cash runway into Q4 2027, giving management more time to advance clinical and preclinical programs before needing additional capital. This improves near-term execution flexibility, although it does not eliminate the company’s longer-term funding needs.
Bears Say
Very Weak And Declining Revenue
Extremely low and declining revenue shows that Addex has not yet established meaningful commercial scale and remains dependent on partnering-related economics. Volatile or limited revenue reduces internal funding capacity and makes future operating results heavily dependent on development milestones.
Persistent Cash Burn And Financing Dependence
Recurring negative operating and free cash flow means the business is not self-funding its research pipeline. Continued dependence on external financing can dilute shareholders or delay programs, as illustrated by the chronic cough work being ready to start only subject to securing capital.
Shrinking Equity And Financial Flexibility
The steep decline in equity reflects the cumulative impact of sustained losses and possible dilution or valuation effects, leaving a smaller financial cushion. Although debt is very low, the reduced equity base limits flexibility to absorb setbacks and fund multiple programs internally.
Addex Therapeutics News
APE1 FAQ
What was Addex Therapeutics’s price range in the past 12 months?
What is Addex Therapeutics’s market cap?
When is Addex Therapeutics’s upcoming earnings report date?
How were Addex Therapeutics’s earnings last quarter?
Is Addex Therapeutics overvalued?
Does Addex Therapeutics pay dividends?
What is Addex Therapeutics’s EPS estimate?
How many shares outstanding does Addex Therapeutics have?
What happened to Addex Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Addex Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Timothy Mark Dyer
- Employees
- 3
- Website
- www.addextherapeutics.com
- Address
- Chemin des Mines, 9, Geneva, GE, 1202, CH
Addex Therapeutics (APE1) Earnings & Revenues
APE1 Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, highlighting a $2.8 million financing, cash runway into Q4 2027, regained rights to the GABAB PAM platform, multiple advancing preclinical and clinical programs, and encouraging chronic cough and substance use disorder data. Offsetting factors included the CHF 0.8 million half-year cash balance, CHF 1.2 million of operating cash use, a stable CHF 3.4 million net loss, increased share of Neurosterix losses, and the need to secure financing before advancing certain programs.
View all DE:APE1 earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 5 | 9 |
| Technical Analysis | 1 | 5 | 2 |
| Moving Averages | 5 | 0 | 7 |
